These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 28774563)

  • 41. Parents' preferences for seasonal influenza vaccine for their children in Japan.
    Shono A; Kondo M
    Vaccine; 2014 Sep; 32(39):5071-6. PubMed ID: 25063570
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.
    Piedra PA; Gaglani MJ; Kozinetz CA; Herschler GB; Fewlass C; Harvey D; Zimmerman N; Glezen WP
    Pediatrics; 2007 Sep; 120(3):e553-64. PubMed ID: 17698577
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.
    Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM
    J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Pilot Prospective Cohort Study in England.
    McNaughton R; Lynn E; Osborne V; Coughtrie A; Layton D; Shakir S
    Drug Saf; 2016 Apr; 39(4):323-33. PubMed ID: 26798051
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) cluster randomized trial: Pilot results from a household surveillance study to assess direct and indirect protection from influenza vaccination.
    Kwong JC; Pereira JA; Quach S; Pellizzari R; Dusome E; Russell ML; Hamid JS; Feinberg Y; Winter AL; Gubbay JB; Sirtonski B; Moher D; Sider D; Finkelstein M; Loeb M;
    Vaccine; 2015 Sep; 33(38):4910-5. PubMed ID: 26232348
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A survey of children's preferences for influenza vaccine attributes.
    Flood EM; Ryan KJ; Rousculp MD; Beusterien KM; Block SL; Hall MC; Mahadevia PJ
    Vaccine; 2011 Jun; 29(26):4334-40. PubMed ID: 21510993
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study).
    Ramsay JA; Jones M; Vande More AM; Hunt SL; Williams PCM; Messer M; Wood N; Macartney K; Lee FJ; Britton WJ; Snelling TL; Caterson ID
    Vaccine; 2023 Nov; 41(48):7250-7258. PubMed ID: 37903680
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season.
    Tennis P; Toback SL; Andrews EB; McQuay LJ; Ambrose CS
    Vaccine; 2012 Sep; 30(42):6099-102. PubMed ID: 22841479
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increasing uptake of live attenuated influenza vaccine among children in the United States, 2008-2014.
    Rodgers L; Pabst LJ; Chaves SS
    Vaccine; 2015 Jan; 33(1):22-4. PubMed ID: 25448098
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Changes in Influenza Vaccination Rates After Withdrawal of Live Vaccine.
    Robison SG; Dunn AG; Richards DL; Leman RF
    Pediatrics; 2017 Nov; 140(5):. PubMed ID: 28986441
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014.
    Haber P; Moro PL; Cano M; Lewis P; Stewart B; Shimabukuro TT
    Vaccine; 2015 Apr; 33(16):1987-92. PubMed ID: 25678241
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the effectiveness of trivalent inactivated influenza vaccine and live, attenuated influenza vaccine in preventing influenza-like illness among US military service members, 2006-2009.
    Phillips CJ; Woolpert T; Sevick C; Faix D; Blair PJ; Crum-Cianflone NF
    Clin Infect Dis; 2013 Jan; 56(1):11-9. PubMed ID: 23183869
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
    Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
    Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses.
    Kiseleva I; Dubrovina I; Fedorova E; Larionova N; Isakova-Sivak I; Bazhenova E; Pisareva M; Kuznetsova V; Flores J; Rudenko L
    Vaccine; 2015 Dec; 33(49):7008-14. PubMed ID: 26432909
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Background paper to the recommendation for the preferential use of live-attenuated influenza vaccine in children aged 2-6 years in Germany.
    Falkenhorst G; Harder T; Remschmidt C; Terhardt M; Zepp F; Ledig T; Wicker S; Keller-Stanislawski B; Mertens T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1557-64. PubMed ID: 24170085
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years.
    Tennis P; Toback SL; Andrews E; McQuay LJ; Ambrose CS
    Vaccine; 2011 Jul; 29(31):4947-52. PubMed ID: 21596087
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
    Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P; Ince D; Noah DL; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1409-19. PubMed ID: 25291577
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004.
    Halloran ME; Piedra PA; Longini IM; Gaglani MJ; Schmotzer B; Fewlass C; Herschler GB; Glezen WP
    Vaccine; 2007 May; 25(20):4038-45. PubMed ID: 17395338
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.
    Rudenko L; Kiseleva I; Stukova M; Erofeeva M; Naykhin A; Donina S; Larionova N; Pisareva M; Krivitskaya V; Flores J;
    Vaccine; 2015 Sep; 33(39):5110-7. PubMed ID: 26296497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.